MEROPENEM; VABORBACTAM | N209776 | REMPEX PHARMACEUTICALS INC A WHOLLY OWNED SUB OF MELINTA THERAPEUTICS LLC
| Patent # | Expiration | PED | Drug Substance | Drug Product | Use Code | Delist |
|---|---|---|---|---|---|---|
| 8680136 | Aug 29, 2031 | — | Yes | Yes | — | — |
| 9694025 | Aug 8, 2031 | — | — | — | — | |
| 10172874 | Aug 8, 2031 | — | — | Yes | — | — |
| 10183034 | Aug 8, 2031 | — | — | — | — | |
| 10561675 | Aug 8, 2031 | — | — | — | — | |
| 11007206 | Aug 8, 2031 | — | — | — | — | |
| 11376237 | Apr 6, 2039 | — | — | — | — | |
| 12171772 | Aug 8, 2031 | — | Yes | — | — | — |
| 12478606 | Jan 8, 2038 | — | — | — | — | |
| 12533342 | May 20, 2039 | — | — | — | — |
| Code | Date | Status |
|---|---|---|
| GAIN | Aug 29, 2027 | Active |
| NCE | Aug 29, 2022 | Expired |
| NCE*GAINNewly listed — daily FDA feed, not yet in monthly Orange Book edition | Aug 29, 2027 | Active |
VABOMERE (meropenem; vaborbactam) gained new chemical entity exclusivity expiring Aug 2027.
New: VABOMERE (MEROPENEM; VABORBACTAM) — exclusivity NCE*GAIN exp 08/29/2027